The global cirrhosis management market is projected to grow from US$ 725 million in 2023 to US$ 1,052.3 million by 2033, with ...

This article explores compensated cirrhosis in more detail, including its causes, diagnosis, and treatment. It also answers some common questions about the condition. Healthcare professionals ...

Sarcopenia is a common complication of decompensated cirrhosis resulting in progressive loss of muscle mass and function. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

The excess copper can damage liver tissue, leading to cirrhosis. 6. Medications and Toxins: Long-term use of certain medications and exposure to toxins can also cause liver damage and cirrhosis.

Ascites is a common complication of cirrhosis. It happens due to the effects of portal hypertension and leads to fluid buildup in your abdomen. Ascites can be treated with medications, procedures ...

LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...

US FDA grants fast track designation to Lipocine’s LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis: Salt Lake City Thursday, December 19, 2024, ...

(LPCN), a biopharmaceutical company, Tuesday said that the U.S. Food and Drug Administration or FDA has granted Fast Track Designation to LPCN 1148, the company's drug candidate for the treatment for ...